1-4 of 4
Edmund A Gehan
Close
Sort by
Journal Articles

Ofatumumab and Bendamustine in Previously Treated CLL and SLL

Chaitra S. Ujjani, MD, Edmund A Gehan, Pari Ramzi, Catherine Broome, MD, Bruce D. Cheson, MD
Journal: Blood
Blood (2011) 118 (21): 4615.
https://doi.org/10.1182/blood.V118.21.4615.4615
Published: 2011
Journal Articles

Bendamustine and Lenalidomide in Relapsed/Refractory CLL

Chaitra S. Ujjani, MD, Syed M. Karim, MD, Trishna Goswami, MD, Jenny Crawford, Edmund A Gehan, Craig M. Kessler, MD, Bruce D. Cheson, MD
Journal: Blood
Blood (2011) 118 (21): 4618.
https://doi.org/10.1182/blood.V118.21.4618.4618
Published: 2011
Journal Articles

Remission Maintenance Therapy for Meningeal Leukemia: Intrathecal Methotrexate vs. Intravenous bis-Nitrosourea

MARGARET P. SULLIVAN, M.D., TERESA J. VIETTI, M.D., MARY ELLEN HAGGARD, M.D., MILTON H. DONALDSON, M.D., JOHN M. KRALL, PH.D., EDMUND A. GEHAN, PH.D.
Journal: Blood
Blood (1971) 38 (6): 680–688.
https://doi.org/10.1182/blood.V38.6.680.680
Published: 1971
Journal Articles

Evaluation of a New Chemotherapeutic Agent in Patients with "Advanced Refractory" Acute Leukemia. Studies of 6-Azauracil

EMIL J. FREIREICH, EMIL FREI, III, JAMES F. HOLLAND, DONALD PINKEL, OLEG SELAWRY, HARVEY ROTHBERG, FARID HAURANI, ROBERT TAYLOR, EDMUND A. GEHAN
Journal: Blood
Blood (1960) 16 (3): 1268–1278.
https://doi.org/10.1182/blood.V16.3.1268.1268
Published: 1960